<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02186418</url>
  </required_header>
  <id_info>
    <org_study_id>ARU-1801_Ph1_01</org_study_id>
    <nct_id>NCT02186418</nct_id>
  </id_info>
  <brief_title>Gene Transfer for Patients With Sickle Cell Disease</brief_title>
  <official_title>Gene Transfer for Patients With Sickle Cell Disease Using a Gamma Globin Lentivirus Vector: An Open Label Phase 1/2 Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell&#xD;
      collection and gamma-globin gene transfer, and success of gene correction in subjects with&#xD;
      sickle cell disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801&#xD;
      (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur&#xD;
      ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood&#xD;
      hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD).&#xD;
      Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan&#xD;
      to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the&#xD;
      study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is&#xD;
      anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in&#xD;
      which all subjects completing the 2 year study visit will be asked to consent and enroll, and&#xD;
      will followed for a further 13 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">July 2038</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2037</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Gamma Globin Lentivirus Vector</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 3 allergic reaction</measure>
    <time_frame>From infusion (Day 0) to 15 years</time_frame>
    <description>Incidence of Grade 3 allergic reaction associated with infusion of transduced cell product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Grade 4 infection</measure>
    <time_frame>From infusion (Day 0) to 15 years</time_frame>
    <description>Incidence of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Grade 4 neutropenia</measure>
    <time_frame>From date of chemotherapy clearance visit to 15 years post-infusion of transduced cells</time_frame>
    <description>Incidence of Grade 4 neutropenia lasting &gt;1 month following melphalan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Grade 3 or 4 organ toxicity</measure>
    <time_frame>From screening to 15 years post-infusion of transduced cells</time_frame>
    <description>Incidence of Grade 3 or 4 organ toxicity attributable to study procedures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From screening to 15 years post-infusion of transduced cells</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>From screening to 15 years post-infusion of transduced cells</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death due to study procedures</measure>
    <time_frame>From screening to 15 years post-infusion of transduced cells</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hematological malignancy</measure>
    <time_frame>From infusion (Day 0) to 15 years</time_frame>
    <description>Incidence of hematological malignancy due to vector insertion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hematological cancer</measure>
    <time_frame>From screening to 15 years post-infusion of transduced cells</time_frame>
    <description>Incidence of hematological cancer related to investigational product or study medications/procedures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil recovery</measure>
    <time_frame>From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells</time_frame>
    <description>Number of days from melphalan-induced nadir to the first of 3 consecutive absolute neutrophil counts ≥500 cells/µL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to platelet recovery</measure>
    <time_frame>From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells</time_frame>
    <description>Number of days from melphalan-induced nadir to the first of 3 consecutive platelet counts &gt;50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>≥8x10⁶kg viable CD34+ cells</measure>
    <time_frame>Up to Year 2</time_frame>
    <description>Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>≥4x10⁶ CD34+ cells/kg body weight transduced</measure>
    <time_frame>Up to Year 2</time_frame>
    <description>Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marrow aspirates with ≥1% gene-marked cells</measure>
    <time_frame>Infusion (Day 0) to 1 year</time_frame>
    <description>Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of Hb (hemoglobin) subtypes</measure>
    <time_frame>Months 6, 12, 18, 24 and year 3, 4, 5</time_frame>
    <description>Quantification of HbF^G16D and other Hb subtypes, including HbF (endogenous), HbS, adult Hb (HbA), HbA2 and, if applicable, HbC and HbE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of antisickling/sickling hemoglobin</measure>
    <time_frame>Baseline to Month 6 through 12</time_frame>
    <description>Change in the proportion of antisickling/sickling hemoglobin ([HbF+HbF^G16D+HbA2]/HbS) in months 6-12 post-transplantation compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of F-RBC (fetal hemoglobin content in red blood cells)</measure>
    <time_frame>Months 6, 12, 18, 24, 36</time_frame>
    <description>Measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of F-retics (fetal hemoglobin content in reticulocytes)</measure>
    <time_frame>Months 6, 12, 18, 24, 36</time_frame>
    <description>Measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of vector copies in white blood cell fraction</measure>
    <time_frame>Days 30, 60, 90, Months 4, 5, 6, 9, 12, 18, 21, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of vector copies in bone marrow</measure>
    <time_frame>Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36</time_frame>
    <description>Measured by qPCR and DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of gene-marked colony-forming unit cells (CFU-c) in bone marrow (BM) indicting gene transfer</measure>
    <time_frame>Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36</time_frame>
    <description>Measured by CFU-c assay by qPCR on individual CFU-c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of annualized vaso-occlusive episodes (VOEs) pre-transplant versus post-transplant</measure>
    <time_frame>Baseline to year 15</time_frame>
    <description>Change in disease severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of opioid use pre-transplant versus post-transplant</measure>
    <time_frame>Baseline to year 15</time_frame>
    <description>Change in disease severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QoL (Quality of Life)</measure>
    <time_frame>Baseline, month 4, 5, 6, 12 and 24 and year 3, 4, 5</time_frame>
    <description>Measured by adult sickle cell quality of life measurement (ASCQ-Me®)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>ARU-1801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ARU-1801</intervention_name>
    <description>Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector&#xD;
Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor&#xD;
Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.</description>
    <arm_group_label>ARU-1801</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Has confirmed diagnosis of sickle cell disease (SCD)&#xD;
&#xD;
          -  Has severe sickle cell disease, defined as one or more of the following:&#xD;
&#xD;
               1. Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS)&#xD;
                  requiring hospital admission, or one life threatening episode of ACS requiring&#xD;
                  intensive care unit (ICU) admission for exchange transfusion and/or intubation,&#xD;
                  or frequent ACS episodes which necessitate treatment with chronic transfusion&#xD;
                  therapy.&#xD;
&#xD;
               2. Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere&#xD;
                  with normal life activities, defined as a history of 2 or more severe acute&#xD;
                  sickle pain events per year requiring additional treatment at a medical facility&#xD;
                  outside of home pain management over the preceding 2-year period prior to study&#xD;
                  enrollment, or that necessitate chronic transfusion therapy.&#xD;
&#xD;
               3. Subjects on chronic transfusion therapy for severe disease symptoms other than&#xD;
                  those listed above, and which interfere with normal life activities.&#xD;
&#xD;
          -  Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has&#xD;
             actively made the choice to not take the recommended daily hydroxyurea advised for&#xD;
             severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell&#xD;
             collection). If refusing hydroxyurea, the subject must document that they have been&#xD;
             educated about the benefits and continue to refuse the treatment. Patients placed on&#xD;
             chronic transfusion therapy instead of hydroxyurea for severe disease are eligible.&#xD;
             Subjects unable to take hydroxyurea due to financial or safety monitoring constraints&#xD;
             are eligible.&#xD;
&#xD;
          -  Has adequate functional status and organ function as determined at Screening.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating/breastfeeding.&#xD;
&#xD;
          -  Female subjects who are not surgically sterile, postmenopausal or who refuse to&#xD;
             practice effective method of birth control as determined by the Investigator for one&#xD;
             year after receiving the study drug. Women must also agree not to breastfeed for 1&#xD;
             year after receiving the study drug.&#xD;
&#xD;
          -  Any participant of reproductive potential who refuses to agree to use an appropriate&#xD;
             contraceptive method determined by the Investigator, for 1 year after receiving the&#xD;
             study drug.&#xD;
&#xD;
          -  Patients with an active malignant disease or receiving treatment for any type of&#xD;
             cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of&#xD;
             the skin).&#xD;
&#xD;
          -  Current diagnosis or history of hepatitis B, hepatitis C, or HIV.&#xD;
&#xD;
          -  Has received another study drug within 30 days, or 5 half-lives of the last dose&#xD;
             (whichever is longer), prior to screening.&#xD;
&#xD;
          -  Has severe obstruction, restriction or diffusion defect on pulmonary function tests.&#xD;
&#xD;
          -  Has uncontrolled bacterial, viral or fungal infections within 1 month prior to&#xD;
             starting the conditioning part of the study. Subjects with fever should wait for&#xD;
             symptoms to resolve before starting the conditioning part of the study.&#xD;
&#xD;
          -  Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving&#xD;
             chronic transfusions or hydroxyurea for primary prevention of stroke; has severe&#xD;
             cerebral vasculopathy defined as moderate stenosis in &gt;2 arterial segments; and/or has&#xD;
             sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of&#xD;
             Moyamoya-like disease).&#xD;
&#xD;
          -  Patients with alpha thalassemia sickle cell disease.&#xD;
&#xD;
          -  Has previous liver biopsy showing cirrhosis, bridging hepatic fibrosis, or active&#xD;
             hepatitis; or has received chronic transfusions and has previous evidence of iron&#xD;
             overload and evidence of liver fibrosis by noninvasive liver imaging.&#xD;
&#xD;
          -  Has a matched sibling donor, unless the subject has declined this option or this&#xD;
             option is not feasible. Documentation must be included as part of the informed consent&#xD;
             process for subjects who decline this option.&#xD;
&#xD;
          -  Has a known hypersensitivity to any study treatments (e.g. melphalan, plerixafor).&#xD;
&#xD;
        Other protocol-defined inclusion-exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stella M. Davies, MB BS, PhD, MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Jamaica</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>July 2023</verification_date>
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>July 18, 2023</last_update_submitted>
  <last_update_submitted_qc>July 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>hemoglobinopathies</keyword>
  <keyword>hematopoietic stem cell</keyword>
  <keyword>gene transfer</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02186418
org study id: ARU-1801_Ph1_01
nct id: NCT02186418
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell
      collection and gamma-globin gene transfer, and success of gene correction in subjects with
      sickle cell disease
This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801
      (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur
      ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood
      hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD).
      Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan
      to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the
      study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is
      anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in
      which all subjects completing the 2 year study visit will be asked to consent and enroll, and
      will followed for a further 13 years.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Gamma Globin Lentivirus Vector
primary purpose: Treatment
masking: None (Open Label)
measure: Incidence of Grade 3 allergic reaction
time frame: From infusion (Day 0) to 15 years
description: Incidence of Grade 3 allergic reaction associated with infusion of transduced cell product
measure: Incidence of Grade 4 infection
time frame: From infusion (Day 0) to 15 years
description: Incidence of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days
measure: Incidence of Grade 4 neutropenia
time frame: From date of chemotherapy clearance visit to 15 years post-infusion of transduced cells
description: Incidence of Grade 4 neutropenia lasting >1 month following melphalan
measure: Incidence of Grade 3 or 4 organ toxicity
time frame: From screening to 15 years post-infusion of transduced cells
description: Incidence of Grade 3 or 4 organ toxicity attributable to study procedures
measure: Incidence of Adverse Events (AEs)
time frame: From screening to 15 years post-infusion of transduced cells
measure: Incidence of Serious Adverse Events (SAEs)
time frame: From screening to 15 years post-infusion of transduced cells
measure: Incidence of death due to study procedures
time frame: From screening to 15 years post-infusion of transduced cells
measure: Incidence of hematological malignancy
time frame: From infusion (Day 0) to 15 years
description: Incidence of hematological malignancy due to vector insertion
measure: Incidence of hematological cancer
time frame: From screening to 15 years post-infusion of transduced cells
description: Incidence of hematological cancer related to investigational product or study medications/procedures
measure: Time to neutrophil recovery
time frame: From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells
description: Number of days from melphalan-induced nadir to the first of 3 consecutive absolute neutrophil counts ≥500 cells/µL
measure: Time to platelet recovery
time frame: From ≥36 hours before Day 0 to 2 years post-infusion of transduced cells
description: Number of days from melphalan-induced nadir to the first of 3 consecutive platelet counts >50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days.
measure: ≥8x10⁶kg viable CD34+ cells
time frame: Up to Year 2
description: Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells
measure: ≥4x10⁶ CD34+ cells/kg body weight transduced
time frame: Up to Year 2
description: Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced
measure: Bone marrow aspirates with ≥1% gene-marked cells
time frame: Infusion (Day 0) to 1 year
description: Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells
measure: Quantity of Hb (hemoglobin) subtypes
time frame: Months 6, 12, 18, 24 and year 3, 4, 5
description: Quantification of HbF^G16D and other Hb subtypes, including HbF (endogenous), HbS, adult Hb (HbA), HbA2 and, if applicable, HbC and HbE
measure: Change in proportion of antisickling/sickling hemoglobin
time frame: Baseline to Month 6 through 12
description: Change in the proportion of antisickling/sickling hemoglobin ([HbF+HbF^G16D+HbA2]/HbS) in months 6-12 post-transplantation compared to baseline
measure: Percentage of F-RBC (fetal hemoglobin content in red blood cells)
time frame: Months 6, 12, 18, 24, 36
description: Measured by flow cytometry
measure: Percentage of F-retics (fetal hemoglobin content in reticulocytes)
time frame: Months 6, 12, 18, 24, 36
description: Measured by flow cytometry
measure: Presence of vector copies in white blood cell fraction
time frame: Days 30, 60, 90, Months 4, 5, 6, 9, 12, 18, 21, 24
measure: Presence of vector copies in bone marrow
time frame: Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36
description: Measured by qPCR and DNA
measure: Presence of gene-marked colony-forming unit cells (CFU-c) in bone marrow (BM) indicting gene transfer
time frame: Prior to ARU-1801 infusion, month 6, 12, 18, 24 and 36
description: Measured by CFU-c assay by qPCR on individual CFU-c
measure: Number of annualized vaso-occlusive episodes (VOEs) pre-transplant versus post-transplant
time frame: Baseline to year 15
description: Change in disease severity
measure: Frequency of opioid use pre-transplant versus post-transplant
time frame: Baseline to year 15
description: Change in disease severity
measure: Change in QoL (Quality of Life)
time frame: Baseline, month 4, 5, 6, 12 and 24 and year 3, 4, 5
description: Measured by adult sickle cell quality of life measurement (ASCQ-Me®)
arm group label: ARU-1801
arm group type: Experimental
description: Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
intervention type: Genetic
intervention name: ARU-1801
description: Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector
Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor
Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.
arm group label: ARU-1801
criteria: 
gender: All
minimum age: 18 Years
maximum age: 45 Years
healthy volunteers: No
last name: Stella M. Davies, MB BS, PhD, MRCP
role: Study Chair
affiliation: Children's Hospital Medical Center, Cincinnati
facility: 
country: United States
country: Canada
country: Jamaica
country: Switzerland
responsible party type: Sponsor
mesh term: Anemia, Sickle Cell
sharing ipd: No